Get the Stockscreener App
0.799
3.15%
-0.026
Pre-market:
.80
0.001
+0.13%
Xilio Therapeutics Inc stock is traded at $0.799, with a volume of 294.19K.
It is down -3.15% in the last 24 hours and down -38.06% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
See More
Previous Close:
$0.825
Open:
$0.82
24h Volume:
294.19K
Relative Volume:
0.08
Market Cap:
$40.00M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2699
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
-14.33%
1M Performance:
-38.06%
6M Performance:
-2.56%
1Y Performance:
+14.14%
1-Day Range:
$0.76
$0.8247
1-Week Range:
$0.729
$0.9595
52-Week Range:
$0.58
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.799 | 40.00M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia
Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com
Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India
Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Xilio Therapeutics, Inc. SEC 10-K Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com
Xilio Lands Massive $2.1B AbbVie Partnership as Phase 2 Cancer Drug Shows Promise - StockTitan
Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online
Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks
AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise
Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS
AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace
Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn
AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business
AbbVie, Xilio Hook up - Baystreet.ca
AbbVie expands oncology R&D with Xilio deal - The Pharma Letter
Xilio Therapeutics, Intel, Lithia Motors - TradingView
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal -February 12, 2025 at 08:42 am EST - Marketscreener.com
Abbvie and Xilio Therapeutics, Inc. Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Marketscreener.com
XLOXilio Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):